Last reviewed · How we verify

NCT07264283

The Progressive Supranuclear Palsy Clinical Trial Platform - Regimen B: LM11A-31

Not yet recruiting Phase 2 Last updated 4 December 2025
What this trial tests

Phase 2 trial testing LM11A-31 in PSP - Progressive Supranuclear Palsy in 147 participants. Not yet recruiting.

Timeline
1 December 2025
Primary endpoint
31 July 2029
31 July 2029

Quick facts

Lead sponsorAdam Boxer
PhasePhase 2
StatusNot yet recruiting
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingquadruple
Primary purposetreatment
Enrollment147
Start date1 December 2025
Primary completion31 July 2029
Estimated completion31 July 2029

Drugs / interventions tested

Conditions studied

Sponsor

Adam Boxer — full company profile →

Who can join

Adults 41 to 86, any sex, with PSP - Progressive Supranuclear Palsy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The Progressive Supranuclear Palsy Clinical Trial Platform (PTP) is a multi-center, multi-regimen clinical trial evaluating the safety and efficacy of investigational products for the treatment of PSP. Regimen B will evaluate the safety and efficacy of a single study drug, LM11A-31, in participants with PSP.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of LM11A-31

Trials testing the same drug.

Other recruiting trials for PSP - Progressive Supranuclear Palsy

Currently open trials in the same condition.

Other Adam Boxer trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07264283.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing